Breaking News, Financial News

Financial Report: Charles River Laboratories

Manufacturing revenue up 18% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Laboratories 2Q Revenues: $341.2 million (+16%) 2Q Earnings: $35.3 million (+29%) YTD Revenues: $640.5 million (+8%) YTD Earnings: $67.5 million (+28%) Comments: Revenue for the Research Models and Services (RMS) segment was $133.1 million in the quarter, up 3%. Discovery and Safety Assessment (DSA) revenue was $142.6 million, up 33% in quarter driven by the acquisition of Argenta and BioFocus, which contributed 22% to DSA revenue. Revenue for the Manufacturing segment was $6...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters